Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

EU-funded project develops mRNA vaccine targeting liver cancer

The European Innovation Council (EIC) is providing approximately €3.8 million in funding for the international research project ADVANCE, in which Universitätsmedizin Frankfurt is participating. The ADVANCE research team aims to develop an mRNA-based cancer vaccine for the treatment of hepatocellular carcinoma (HCC).

Published by
News-Medical
Evidence type
Industry

The European Innovation Council (EIC) is providing approximately €3.8 million in funding for the international research project ADVANCE, in which Universitätsmedizin Frankfurt is participating. The ADVANCE research team aims to develop an mRNA-based cancer vaccine for the treatment of hepatocellular carcinoma (HCC).

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at News-Medical.

Gene Delivery & TransfectionLipid Nanoparticles & RNA Therapeutics

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
EU-funded project develops mRNA vaccine targeting liver cancer | Brilliant Blue Biosciences